Phoenix Financial Ltd. Lowers Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Key Points

• Phoenix Financial Ltd. has reduced its holdings in Regeneron Pharmaceuticals by 75.3%, selling 1,584 shares and now owning only 519 shares valued at $329,000.
• Multiple institutional investors increased their stakes in Regeneron Pharmaceuticals, with Capital International Investors boosting theirs by 41.6% in the last quarter.
• Recent analyst ratings indicate a mixed outlook for Regeneron, with a consensus price target of $837.61 and several firms adjusting their price objectives downward.

Phoenix Financial Ltd. lessened its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 75.3% during the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 519 shares of the biopharmaceutical company's stock after selling 1,584 shares during the period. Phoenix Financial Ltd.'s holdings in Regeneron Pharmaceuticals were worth $329,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of REGN. Brighton Jones LLC raised its holdings in Regeneron Pharmaceuticals by 261.8% during the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company's stock valued at $675,000 after buying an additional 686 shares during the period. American Assets Inc. purchased a new stake in Regeneron Pharmaceuticals in the fourth quarter worth $427,000. Quantbot Technologies LP increased its stake in Regeneron Pharmaceuticals by 266.7% in the fourth quarter. Quantbot Technologies LP now owns 528 shares of the biopharmaceutical company's stock worth $376,000 after purchasing an additional 384 shares during the period. UniSuper Management Pty Ltd increased its stake in Regeneron Pharmaceuticals by 38.0% in the fourth quarter. UniSuper Management Pty Ltd now owns 7,306 shares of the biopharmaceutical company's stock worth $5,204,000 after purchasing an additional 2,013 shares during the period. Finally, New Age Alpha Advisors LLC increased its stake in Regeneron Pharmaceuticals by 59,271.4% in the fourth quarter. New Age Alpha Advisors LLC now owns 8,312 shares of the biopharmaceutical company's stock worth $5,921,000 after purchasing an additional 8,298 shares during the period. Hedge funds and other institutional investors own 83.31% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. Robert W. Baird reduced their target price on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating on the stock in a research note on Friday, April 25th. Canaccord Genuity Group reiterated a "buy" rating and issued a $850.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, July 23rd. Bank of America reduced their target price on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating on the stock in a research note on Thursday, April 17th. Wells Fargo & Company downgraded Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and lowered their price target for the stock from $700.00 to $580.00 in a report on Friday, May 30th. Finally, Guggenheim reissued a "buy" rating on shares of Regeneron Pharmaceuticals in a report on Friday, May 30th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $837.61.

Regeneron Pharmaceuticals Trading Down 0.4%

Shares of REGN stock traded down $2.37 on Wednesday, hitting $555.78. The stock had a trading volume of 98,691 shares, compared to its average volume of 1,110,778. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.93 and a quick ratio of 4.03. The firm has a market capitalization of $60.00 billion, a P/E ratio of 14.12, a P/E/G ratio of 2.10 and a beta of 0.33. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,211.20. The company's 50 day moving average price is $540.67 and its 200-day moving average price is $606.53.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.83 by ($0.61). The business had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. The company's revenue was down 3.7% compared to the same quarter last year. During the same period in the prior year, the company posted $9.55 earnings per share. Analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were given a $0.88 dividend. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.63%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.96%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.